Akari Therapeutics (AKTX) investor relations material

Executive summary

• Advanced lead ADC program AKTX-101 through IND-enabling activities, targeting Phase 1 clinical trial initiation in mid-2027, with pipeline expansion as capital allows.

• No commercial products or revenue; operations funded by equity and debt financings.

• Entered a strategic research collaboration with Whitehawk Therapeutics to explore dual-payload ADCs, expanding the PH1 platform's potential.

• Presented positive preclinical data for AKTX-101 at major oncology conferences, including ASCO 2026, showing synergistic anti-tumor activity of PH1 payload with KRAS inhibitor in pancreatic cancer models.

Financial highlights

• Net loss for Q2 2026 was $4.8 million, compared to $1.9 million in Q2 2025; net loss for the six months ended June 30, 2026 was $19.3 million, up from $5.6 million year-over-year.

• Operating expenses for Q2 2026 were $4.6 million, up from $3.1 million in Q2 2025, mainly due to increased R&D activities.

• Non-cash impairment charges of $3.7 million (IPR&D) and $8.4 million (goodwill) recorded in the first half of 2026.

• Cash and restricted cash at June 30, 2026 totaled $7.7 million, up from $5.2 million at year-end 2025; accumulated deficit reached $283.8 million.

• Raised approximately $8.6 million in gross proceeds during the quarter through private placement and warrant exercises, resulting in $8.0 million net proceeds.

Outlook and guidance

• Cash runway expected to last into December 2026; additional capital will be required to continue operations beyond that point.

• IND-enabling studies for AKTX-101 are ongoing, with a goal to start First-In-Human trial by mid-2027, contingent on successful IND-enabling activities and funding.

• Ongoing efforts to secure further funding through equity, debt, or strategic collaborations.

• Continued focus on expanding the ADC pipeline and leveraging the PH1 platform for future growth.